Lipid Panel With GlycA (Inflammation) and Diabetes Risk Index (DRI)
Use
The Lipid Panel with GlycA and Diabetes Risk Index (DRI) is designed to assess both lipid profiles and inflammation status within individuals. GlycA serves as a composite biomarker that integrates protein levels and glycosylation of acute-phase proteins, providing a stable measure of systemic inflammation with lower intra-individual variability compared to traditional markers like hsCRP. The DRI score, ranging from 1 to 100, uses NMR spectroscopy to gauge the risk of developing type 2 diabetes by analyzing lipoprotein particle size, insulin resistance indices, and levels of branched-chain amino acids. This test ultimately aids in stratifying cardiovascular and diabetes risks, particularly for individuals who are normoglycemic or prediabetic.
Special Instructions
Patients should not be expected to fast unless triglyceride values are of diagnostic concern, such as in familial hypercholesterolemia or confirming hypertriglyceridemia. The NMR method for triglycerides circumvents endogenous glycerol interference, making it useful in specific X-linked genetic disorders like Hyperglycerolemia. Results may differ substantially from those derived through chemical methods due to glycerol levels.
Limitations
LDL cholesterol will not be calculated if triglyceride levels exceed 800 mg/dL. Significant variances in GlycA readings arise from differences in specimen types (e.g., EDTA plasma vs. serum), and hemolysis may lower GlycA by more than 10%. DRI results from plasma specimens are typically eight points lower than those from serum, necessitating context consideration. High triglyceride values in frozen samples may decrease by more than 10%. This test's performance characteristics are not cleared or approved by the FDA.
Methodology
Other
Biomarkers
LOINC Codes
- 2093-3
- 2571-8
- 2085-9
- 43396-1
- 13457-7
- 82730-3
- 94560-0
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plain red-top tube (preferred); NMR LipoTube (black-and-yellow-top tube), lavender-top (EDTA-no gel) tube or green-top (heparin-no gel) tube
Collection Instructions
Collect specimen in plain red-top tube (no gel). Hold tube at room temperature for 45 minutes to allow clotting. Centrifuge accordingly and transfer to transport tube for 2°C to 8°C storage until shipped.
Patient Preparation
Patient fasting is not required unless indicated by prior diagnostic conditions.
Storage Instructions
Refrigerate specimens at 2°C to 8°C.
Causes for Rejection
Unspun LipoTube or unseparated red-top or EDTA tubes, use of gel-barrier tubes other than NMR LipoTube, hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | LipoTube Serum: 1 day; Plain Serum: 1 day; EDTA Plasma: 8 hours; Sodium Heparin Plasma: 8 hours |
| Refrigerated | LipoTube Serum: 8 days; Plain Serum: 8 days; EDTA Plasma: 8 days; Sodium Heparin Plasma: 7 days |
| Frozen | All tubes: 14 days |